Feng Ye1, Shanzhi Wang2, Min Wang1, Huanan Wang1, Feng Guo1, Guoquan Li1, Nan Liu2. 1. Department of Rheumatology and Immunology, The First Affiliated Hospital of Hainan Medical University Haikou City 570102, Hainan Province, China. 2. Department of Nephrology, The First Affiliated Hospital of Hainan Medical University Haikou City 570102, Hainan Province, China.
Abstract
OBJECTIVE: To observe the efficacy and safety of multi-target (tacrolimus + mycophenolate mofetil + prednisone) therapy for type III + V and IV + V type lupus nephritis. METHODS: A total of 56 patients with lupus nephritis were randomly divided into a treatment group receiving multi-target treatment and a control group receiving intravenous cyclophosphamide combined with prednisone treatment, with 28 patients in each group. Clinical indicators and adverse reactions were observed before and 4, 12, 24, 48 and 72 weeks after treatment. RESULTS: One patient withdrew from the treatment group and two patients from the control group due to adverse reactions within 72 weeks of treatment. Compared with those before treatment, urine protein quantification, ds-DNA antibody titer and systemic lupus erythematosus disease activity index (SLEDAI) scores were significantly decreased at 24 h after 72 weeks of treatment in both groups (P < 0.05). The total remission rate was 85.2% in the treatment group and 57.7% in the control group (P < 0.05) and dte total response rate was 59.3% and 30.8%, respectively (P < 0.05). CONCLUSION: Multiple target treatment of type III + V or IV + V type lupus nephritis has a higher total remission rate, a shorter treatment time, and a lower incidence of adverse reactions than cyclophosphamide and prednisone combined therapy. AJTR
OBJECTIVE: To observe the efficacy and safety of multi-target (tacrolimus + mycophenolate mofetil + prednisone) therapy for type III + V and IV + V type lupus nephritis. METHODS: A total of 56 patients with lupus nephritis were randomly divided into a treatment group receiving multi-target treatment and a control group receiving intravenous cyclophosphamide combined with prednisone treatment, with 28 patients in each group. Clinical indicators and adverse reactions were observed before and 4, 12, 24, 48 and 72 weeks after treatment. RESULTS: One patient withdrew from the treatment group and two patients from the control group due to adverse reactions within 72 weeks of treatment. Compared with those before treatment, urine protein quantification, ds-DNA antibody titer and systemic lupus erythematosus disease activity index (SLEDAI) scores were significantly decreased at 24 h after 72 weeks of treatment in both groups (P < 0.05). The total remission rate was 85.2% in the treatment group and 57.7% in the control group (P < 0.05) and dte total response rate was 59.3% and 30.8%, respectively (P < 0.05). CONCLUSION: Multiple target treatment of type III + V or IV + V type lupus nephritis has a higher total remission rate, a shorter treatment time, and a lower incidence of adverse reactions than cyclophosphamide and prednisone combined therapy. AJTR
Authors: Anders I Olin; Matthias Mörgelin; Lennart Truedsson; Gunnar Sturfelt; Anders A Bengtsson Journal: Arthritis Rheumatol Date: 2014-02 Impact factor: 10.995
Authors: Yingkai Li; Jeffrey T Guptill; Melissa A Russo; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; James F Howard; Manisha Chopra; Weibin Liu; John S Yi Journal: Exp Neurol Date: 2018-11-22 Impact factor: 5.330
Authors: R Sakai; T Kurasawa; E Nishi; T Kondo; Y Okada; A Shibata; K Nishimura; K Chino; A Okuyama; H Takei; H Nagasawa; K Amano Journal: Lupus Date: 2017-07-06 Impact factor: 2.911
Authors: Desmond Y H Yap; Colin S O Tang; Maggie K M Ma; Man Fai Lam; Tak Mao Chan Journal: Nephrol Dial Transplant Date: 2012-04-20 Impact factor: 5.992
Authors: Robert S Flanc; Matthew A Roberts; Giovanni F M Strippoli; Steven J Chadban; Peter G Kerr; Robert C Atkins Journal: Am J Kidney Dis Date: 2004-02 Impact factor: 8.860